New chemo cocktail aims to slow advanced colon cancer
NCT ID NCT07621497
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a new chemotherapy regimen called FOLFOX8 against the standard mFOLFOX6, both combined with targeted drugs (bevacizumab or cetuximab), as a first treatment for people with metastatic colorectal cancer that cannot be surgically removed. About 229 participants will be randomly assigned to one of the two regimens. The main goal is to see if FOLFOX8 delays cancer growth longer than the standard approach.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- FOLFOX8 (oxaliplatin, 5-fluorouracil, levofolinic acid) and mFOLFOX6 combined with bevacizumab or cetuximab
- What this could lead to
- If successful, this could lead to a more effective first-line chemotherapy regimen for people with advanced colorectal cancer that cannot be removed by surgery.
- What could go wrong
- This is an early Phase 2 trial with only 229 participants, so results may not apply to all patients. The new regimen may not improve survival and could have side effects like nerve damage or low blood counts.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC COLORECTAL CANCER (CRC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, 510000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can mindfulness together ease the burden of advanced cancer?
- Can a Two-Pronged attack shrink Hard-to-Treat colorectal tumors?
- Blood test may reveal hidden cancer spread without scans
- Mouth bacteria may predict colon cancer drug resistance
- Smart dosing: tailoring cancer drug levels could extend life for colorectal patients
- New antibody combo takes on tough colorectal cancer